UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer

PloS one, 2013-06, Vol.8 (6), p.e66502-e66502

2013

Volltextzugriff (PDF)

ubiquitin ligase COP1 is a critical negative regulator of p53

Nature, 2004-05, Vol.429 (6987), p.86-92

2004

Volltextzugriff (PDF)

TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer

Science signaling, 2011-06, Vol.4 (177), p.ra41

2011

Volltextzugriff (PDF)

Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

Blood, 2009-09, Vol.114 (13), p.2721-2729

2009

Volltextzugriff (PDF)

Human De-Etiolated-1 Regulates c-Jun by Assembling a CUL4A Ubiquitin Ligase

Science (American Association for the Advancement of Science), 2004-02, Vol.303 (5662), p.1371-1374

2004

Volltextzugriff (PDF)

Abstract ND11: EO-3021: An antibody drug conjugate targeting CLDN18.2 expressing cancers

Cancer research (Chicago, Ill.), 2023-05, Vol.83 (7_Supplement), p.ND11-ND11

Dornan, David

2023

Volltextzugriff (PDF)

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

Haematologica (Roma), 2012-06, Vol.97 (6), p.937-942

2012

Volltextzugriff (PDF)

Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls

BMC cancer, 2013-11, Vol.13 (1), p.554-554, Article 554

2013

Volltextzugriff (PDF)

ATM Engages Autodegradation of the E3 Ubiquitin Ligase COP1 After DNA Damage

Science (American Association for the Advancement of Science), 2006-08, Vol.313 (5790), p.1122-1126

2006

Volltextzugriff (PDF)

Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer

Cancer medicine (Malden, MA), 2014-10, Vol.3 (5), p.1136-1145

2014

Volltextzugriff (PDF)

COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas

Cancer research (Chicago, Ill.), 2004-10, Vol.64 (20), p.7226-7230

2004

Volltextzugriff (PDF)

Effect of FCGR2A and FCGR3A variants on CLL outcome

Blood, 2010-11, Vol.116 (20), p.4212-4222

2010

Volltextzugriff (PDF)

To respond or not to respond to CD40 agonism: That is the prediction

Oncoimmunology, 2012-01, Vol.1 (1), p.83-85

2012

Volltextzugriff (PDF)

605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A640-A640

2020

Volltextzugriff (PDF)

784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A819-A819

2021

Volltextzugriff (PDF)

603 Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A638-A638

2020

Volltextzugriff (PDF)

DNA-dependent Acetylation of p53 by the Transcription Coactivator p300

The Journal of biological chemistry, 2003-04, Vol.278 (15), p.13431-13441

2003

Volltextzugriff (PDF)

The Proline Repeat Domain of p53 Binds Directly to the Transcriptional Coactivator p300 and Allosterically Controls DNA-Dependent Acetylation of p53

Molecular and Cellular Biology, 2003-12, Vol.23 (23), p.8846-8861

2003

Volltextzugriff (PDF)

Interferon Regulatory Factor 1 Binding to p300 Stimulates DNA-Dependent Acetylation of p53

Molecular and Cellular Biology, 2004-11, Vol.24 (22), p.10083-10098

2004

Volltextzugriff (PDF)

The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo

The Journal of biological chemistry, 2002-08, Vol.277 (32), p.28446-28458

2002

Volltextzugriff (PDF)

401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A426-A426

2020

Volltextzugriff (PDF)

Dissecting cancer heterogeneity

Nature biotechnology, 2011-12, Vol.29 (12), p.1095-1096

2011

Volltextzugriff (PDF)

Reply to "Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?" Haematologica. 2012;97(11):e45

Haematologica (Roma), 2012-11, Vol.97 (11), p.e46-e46

2012

Volltextzugriff (PDF)

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

Nature (London), 2010-01, Vol.463 (7277), p.103-107

2010

Volltextzugriff (PDF)

Abstract 3121: Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.3121-3121

2024

Volltextzugriff (PDF)

1 – 25 von 187

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(167)
Mit Volltextzugriff
(169)

Publikationsform

Sprache

Englisch
(186)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer

ubiquitin ligase COP1 is a critical negative regulator of p53

TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer

Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

Human De-Etiolated-1 Regulates c-Jun by Assembling a CUL4A Ubiquitin Ligase

Abstract ND11: EO-3021: An antibody drug conjugate targeting CLDN18.2 expressing cancers

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls

ATM Engages Autodegradation of the E3 Ubiquitin Ligase COP1 After DNA Damage

Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer

COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas

Effect of FCGR2A and FCGR3A variants on CLL outcome

To respond or not to respond to CD40 agonism: That is the prediction

605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models

784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors

603 Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration

DNA-dependent Acetylation of p53 by the Transcription Coactivator p300

The Proline Repeat Domain of p53 Binds Directly to the Transcriptional Coactivator p300 and Allosterically Controls DNA-Dependent Acetylation of p53

Interferon Regulatory Factor 1 Binding to p300 Stimulates DNA-Dependent Acetylation of p53

The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo

401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Dissecting cancer heterogeneity

Reply to "Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?" Haematologica. 2012;97(11):e45

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

Abstract 3121: Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers

Suchergebnisse filtern